472 related articles for article (PubMed ID: 30322215)
1. Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?
Lambert M; Capuano V; Olschewski A; Sabourin J; Nagaraj C; Girerd B; Weatherald J; Humbert M; Antigny F
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30322215
[TBL] [Abstract][Full Text] [Related]
2. Modulation of ion channels in pulmonary arterial hypertension.
Guibert C; Marthan R; Savineau JP
Curr Pharm Des; 2007; 13(24):2443-55. PubMed ID: 17692012
[TBL] [Abstract][Full Text] [Related]
3. Role of Store-Operated Ca
Masson B; Montani D; Humbert M; Capuano V; Antigny F
Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944425
[TBL] [Abstract][Full Text] [Related]
4. Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension.
Santos-Gomes J; Le Ribeuz H; Brás-Silva C; Antigny F; Adão R
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454073
[TBL] [Abstract][Full Text] [Related]
5. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F
Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814
[TBL] [Abstract][Full Text] [Related]
6. Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.
Le Ribeuz H; Capuano V; Girerd B; Humbert M; Montani D; Antigny F
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32882918
[TBL] [Abstract][Full Text] [Related]
7. Ion channels as convergence points in the pathology of pulmonary arterial hypertension.
Jouen-Tachoire TRH; Tucker SJ; Tammaro P
Biochem Soc Trans; 2021 Aug; 49(4):1855-1865. PubMed ID: 34346486
[TBL] [Abstract][Full Text] [Related]
8. Ion channels and transporters as therapeutic targets in the pulmonary circulation.
Olschewski A; Papp R; Nagaraj C; Olschewski H
Pharmacol Ther; 2014 Dec; 144(3):349-68. PubMed ID: 25108211
[TBL] [Abstract][Full Text] [Related]
9. The pharmacological treatment of pulmonary arterial hypertension.
Frumkin LR
Pharmacol Rev; 2012 Jul; 64(3):583-620. PubMed ID: 22659328
[TBL] [Abstract][Full Text] [Related]
10. Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension.
Redel-Traub G; Sampson KJ; Kass RS; Bohnen MS
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291551
[TBL] [Abstract][Full Text] [Related]
11. Potassium channels in pulmonary arterial hypertension.
Boucherat O; Chabot S; Antigny F; Perros F; Provencher S; Bonnet S
Eur Respir J; 2015 Oct; 46(4):1167-77. PubMed ID: 26341985
[TBL] [Abstract][Full Text] [Related]
12. Endothelin antagonism in pulmonary arterial hypertension.
Lee SH; Channick RN
Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
[TBL] [Abstract][Full Text] [Related]
13. Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension.
Bonnet S; Archer SL
Pharmacol Ther; 2007 Jul; 115(1):56-69. PubMed ID: 17583356
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Heterozygous
Bohnen MS; Roman-Campos D; Terrenoire C; Jnani J; Sampson KJ; Chung WK; Kass RS
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28889099
[TBL] [Abstract][Full Text] [Related]
15. Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.
Oishi P; Datar SA; Fineman JR
Expert Opin Pharmacother; 2011 Aug; 12(12):1845-64. PubMed ID: 21609302
[TBL] [Abstract][Full Text] [Related]
16. ORAI Channels as Potential Therapeutic Targets in Pulmonary Hypertension.
Rode B; Bailey MA; Marthan R; Beech DJ; Guibert C
Physiology (Bethesda); 2018 Jul; 33(4):261-268. PubMed ID: 29897302
[TBL] [Abstract][Full Text] [Related]
17. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension.
Moudgil R; Michelakis ED; Archer SL
Microcirculation; 2006 Dec; 13(8):615-32. PubMed ID: 17085423
[TBL] [Abstract][Full Text] [Related]
18. The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies.
Jasińska-Stroschein M; Orszulak-Michalak D
Pharmacol Rep; 2014 Aug; 66(4):552-64. PubMed ID: 24948054
[TBL] [Abstract][Full Text] [Related]
19. Transient Receptor Potential Channel 4 Encodes a Vascular Permeability Defect and High-Frequency Ca(2+) Transients in Severe Pulmonary Arterial Hypertension.
Francis M; Xu N; Zhou C; Stevens T
Am J Pathol; 2016 Jun; 186(6):1701-9. PubMed ID: 27083517
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.
Vaidya B; Gupta V
J Control Release; 2015 Aug; 211():118-33. PubMed ID: 26036906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
